摘要
目的探讨2型糖尿病患者ATM rs11212617、SLC22A1 rs628031多态性与二甲双胍疗效的关系。方法通过PubMed、Web of Science、Cochrane Library及中国知网等数据库系统全面检索ATM rs11212617、SLC22A1 rs628031多态性与2型糖尿病患者单用二甲双胍疗效关系的相关文献。检索时限均从建库至2022年11月2日。以纽卡斯尔-渥太华量表(the Newcastle-Ottawa scale,NOS量表)为准进行文献质量评价,然后提取资料和数据。以糖化血红蛋白(HbA1c)变化值作为效应量进行数据合并,采用Review Manager 5.4分析进行Meta分析。结果经过筛选共有8个研究符合标准,共计1199例患者。其中4项研究关注ATM rs11212617位点,总共596例患者;4项研究关注SLC22A1 rs628031位点,总共603例患者。ATM rs11212617与2型糖尿病患者使用二甲双胍效果并无显著关联。对于SLC22A1 rs628031,AG基因型携带者使用二甲双胍比GG基因型携带者能获得更大的HbA1c降低效果[MD=-0.19,95%CI(-0.36,-0.02),P=0.03],该结果需要更多样本的确认,因为在敏感性分析中发现结果有显著变化。结论基于本研究结果,2型糖尿病患者ATM rs11212617基因多态性对二甲双胍的疗效没有显著影响。而SLC22A1 rs628031 AG型患者可能会比GG型患者获得更好的降低HbA1c效果,但仍需要更进一步确认。
OBJECTIVE To explore the association between the ATM rs11212617,SLC22A1 rs628031 polymorphisms and the metformin response in patients with type 2 diabetes.METHODS Studies about ATM rs11212617,SLC22A1 rs628031 polymorphisms and the metformin response in patients with type 2 diabetes published until November 1,2022,were retrieved from PubMed,Web of Science,Cochrane library,and CNKI.The literature was evaluated with the Newcastle Ottawa scale(NOS),and then the data and information were extracted.The change value of glycosylated hemoglobin(HbA1c) was used as the effect quantity for data merging,and the meta-analysis was implemented with Rev Man 5.4 software.RESULTS A total of 8 studies involving 1 199 patients were included in this Meta-analysis.Among them,4 studies focused on ATM rs11212617,with a total of 596 patients.4 studies focused on SLC22A1 rs628031,with a total of 603 patients.There was no significant association between the ATM rs11212617 polymorphism and metformin therapeutic efficacy in type 2 diabetes patients.For SLC22A1 rs628031,AG genotype carriers obtained greater HbA1c reduction effect by using metformin than GG genotype carriers [MD=-0.19,95% CI(-0.36,-0.02),P=0.03].However,this result needed to be confirmed by more samples,because significant changes were found in the sensitivity analysis.CONCLUSION Based on the results of this study,ATM rs11212617 gene polymorphism in type 2 diabetes patients has no significant impact on the efficacy of metformin.SLC22A1 rs628031 AG patients may have better effect on reducing the level of HbA1c than GG patients,but further confirmation is still needed.
作者
余丽娴
李金贤
任艳玲
杨泽锐
YU Lixian;LI Jinxian;REN Yanling;YANG Zerui(Key Specialty of Clinical Pharmacy,The First Affiliated Hospital of Guangdong Pharmaceutical University,Guangzhou,Guangdong 510000,China;NMPA Key Laboratory for Technology Research and Evaluation of Pharmacovigilance,Guangdong Pharmaceutical University,Guangzhou,Guangdong 510006,China)
出处
《今日药学》
CAS
2023年第8期620-625,635,共7页
Pharmacy Today